Association of Amisulpride Response in Schizophrenia With Brain Image
NCT ID: NCT02095938
Last Updated: 2014-03-26
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2014-01-31
Study Completion Date
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Study rationale - Nielsen et al reported that after 6 weeks of amisulpride treatment, patients with schizophrenia showed an increase in the anticipation-related functional MRI signal. This suggested that amisulpride could affect the brain structures and that responses to amisulpride could be associated by the brain structures as seen previous studies about treatment response to antipsychotics and brain structures. But to date, no study has examined the impact of brain structure alterations on amisulpride treatment for schizophrenia and its potential clinical significance.
2. Study Objectives 2-1. Primary: To show the differences of the baseline brain structures on the structural MRI between the Solian® treatment responders and the non-responders 2-2. Secondary: To show the differences of the baseline polymorphisms of COMT and BDNF with molecular genetic analysis between the Solian® treatment responders and the non-responders responder defined by PANSS. To find out the correlates of baseline brain structures with symptom severity of schizophrenia at baseline; symptom severity defined by CGI-S and PANSS. To assess psychotic symptom improvement after 8th week of Solian® treatment using PANSS, SANS, SAPS and CGI. To assess safety after 8th week of Solian® treatment with Barnes Akathisia Scale, Simpson-Angus scale and vital signs. To report all serious adverse event within 24hrs regardless of relationship to investigational product.
3. Study Design: Prospective/ Open label/ Interventional/ Controlled
4. Evaluation Criteria:
5-1. Primary endpoints: Brain structures on the structural MRI will be observed before the treatment starts. Based on the clinical response after treatment, patients will be divided in the two different groups as follow and their baseline brain structure of will be compared. Treatment responders and non-responders.
5-2. Secondary endpoints: The relationship of baseline brain structures with symptom severity of schizophrenia. Severity will be determined by CGI-S and PANSS at baseline. The differences of the polymorphisms of COMT and BDNF with molecular genetic analysis using patients' peripheral blood, especially leukocytes, between the treatment responders and the non-responders. Efficacy - PANSS, SANS, SAPS, CGI. Safety - Barnes akathisia scale, Simpson-Angus scale, Vital signs
2. Study Objectives 2-1. Primary: To show the differences of the baseline brain structures on the structural MRI between the Solian® treatment responders and the non-responders 2-2. Secondary: To show the differences of the baseline polymorphisms of COMT and BDNF with molecular genetic analysis between the Solian® treatment responders and the non-responders responder defined by PANSS. To find out the correlates of baseline brain structures with symptom severity of schizophrenia at baseline; symptom severity defined by CGI-S and PANSS. To assess psychotic symptom improvement after 8th week of Solian® treatment using PANSS, SANS, SAPS and CGI. To assess safety after 8th week of Solian® treatment with Barnes Akathisia Scale, Simpson-Angus scale and vital signs. To report all serious adverse event within 24hrs regardless of relationship to investigational product.
3. Study Design: Prospective/ Open label/ Interventional/ Controlled
4. Evaluation Criteria:
5-1. Primary endpoints: Brain structures on the structural MRI will be observed before the treatment starts. Based on the clinical response after treatment, patients will be divided in the two different groups as follow and their baseline brain structure of will be compared. Treatment responders and non-responders.
5-2. Secondary endpoints: The relationship of baseline brain structures with symptom severity of schizophrenia. Severity will be determined by CGI-S and PANSS at baseline. The differences of the polymorphisms of COMT and BDNF with molecular genetic analysis using patients' peripheral blood, especially leukocytes, between the treatment responders and the non-responders. Efficacy - PANSS, SANS, SAPS, CGI. Safety - Barnes akathisia scale, Simpson-Angus scale, Vital signs
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia
NCT01795183
Schizophrenia
COMPLETED
PHASE4
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981
Schizoaffective Disorder
Schizophrenia
COMPLETED
Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
NCT00001284
Genotype
Allelic Frequencies of Genetic Markers
Brain Mapping
+2 more
COMPLETED
Minocycline for Schizophrenia
NCT01809158
Schizophrenia
COMPLETED
PHASE4
Memantine for the Prevention of Cognitive Dysfunction and Negative Symptoms in Patients With Acute Schizophrenia
NCT00148590
Schizophrenia
TERMINATED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Study rationale 1-1.
* Predicting the treatment response of antipsychotic drug in schizophrenia patients has been an issue in psychiatry. However, it is not clear if the findings of structural magnetic resonance imaging (MRI) such as brain gray matter volumes and white matter connectivities, are related to the treatment response of antipsychotic drugs.
* The cognitive and behavioural symptoms of patients with schizophrenia are hypothesized to involve a disruption of neuronal interactions resulting in dysfunctional cognitive integration (Friston et al., 1995, 1996). This hypothesis is supported by reports about a decrease in white matter anatomic connections (Mitelman et al. 2006; Skudlarski et al. 2010; Zalesky et al. 2011) and brain structure alterations, especially decrease in volumes of specific brain regions for patients with schizophrenia. Several studies of brain connectivity have shown that functional connectivity depends strongly on the underlying anatomic structure (Sporns O et al. 2004). At the anatomic level, the pathology of schizophrenia has been related to a wide range of anatomic abnormalities, including ventricular enlargement, associated with anomalous neurodevelopment or neurodegenerative alterations (Shenton ME et al 2001). And schizophrenia is likely to be the result of both general and specific localized changes in both grey and white matter (Knochel C et al. 2012; Konrad A et al. 2008). Savas HA et al. found that responders to risperidone had greater hippocampal volumes than patients who failed to respond to risperidone (Savas HA et al., 2002). Vicente M et al. found an inverse association between striatal size and the degree of clinical improvement, and a direct association between the degree of insular volume deficit and its improvement. The non-responders to risperidone or olanzapine showed a significant decrease in their left rectal gyrus as compared with the responder group. (Vicente M et al., 2010).
* Nielsen et al reported that after 6 weeks of amisulpride treatment, patients with schizophrenia showed an increase in the anticipation-related functional MRI signal (Nielsen et al., 2012). This suggested that amisulpride could affect the brain structures and that responses to amisulpride could be associated by the brain structures as seen previous studies about treatment response to antipsychotics and brain structures. But to date, no study has examined the impact of brain structure alterations on amisulpride treatment for schizophrenia and its potential clinical significance..
2. Study type: Clinical Study Phase IV
3. Number of centers: a single center in Korea
4. Number of subjects: N= 20 patients
5. Study duration and dates (format date : dd/mmm/yyyy) 5-1. Protocol planned date: 01/Apr/2013 5-2. First patient In: 01/Nov/2013 5-3. Last patient In: 01/Oct/2015 5-4. Last patient Out: 01/Dec/2015 5-5. Estimated enrollment duration: 2 years 5-6. Estimated average treatment duration: 8 weeks 5-7. Database lock planned date: 15/Dec/2015 5-8. Estimated Report/Publication date: 31/Dec/2015
6. Indication: Schizophrenia
7. Study Objectives (Primary / Most Important Secondary):
7-1. Primary: To show the differences of the baseline brain structures on the structural MRI between the Solian® treatment responders and the non-responders 7-2. Secondary:
* To show the differences of the baseline polymorphisms of COMT and BDNF with molecular genetic analysis between the Solian® treatment responders and the non-responders; responder defined by PANSS
* To find out the correlates of baseline brain structures with symptom severity of schizophrenia at baseline; symptom severity defined by CGI-S and PANSS
* To assess psychotic symptom improvement after 8th week of Solian® treatment using positive and negative syndrome scale (PANSS), scale for the assessment of negative symptoms (SANS), scale for the assessment of positive symptoms (SAPS) and clinical global impression scale (CGI)
* To assess safety after 8th week of Solian® treatment with Barnes Akathisia Scale, Simpson-Angus scale and vital signs
* To report all serious adverse event (SAE) within 24hrs regardless of relationship to investigational product. SAE or expedited reports are completed including: death, Requiring/prolonging hospitalization, Congenital anomaly/Birth defect, Life-threatening, Persistent/significant disability/incapacity, A procedure result only if symptomatic, considered by the investigator as clinically significant or meaningful or leading to permanent investigational product discontinuation or requiring corrective treatment, A symptomatic overdose, A pregnancy, AESI (adverse event special interest with immediate notification) in AEs( serious or non-serious) that need to be monitored, documented, and managed in a pre-specified manner described in the protocol.
8. Inclusion Criteria:
8-1. between 21 and 60 years of age 8-2. diagnosed with schizophrenia, based on the Structured Clinical Interview for DSM-IV(SCID) 8-3. first or second episode of schizophrenia patient 8-4. the presence of positive or negative symptoms or both, resulting in illness of at least mild severity (≥3 on the Clinical Global Impression (CGI) severity scale
9. Exclusion Criteria:
9-1. evidence of organic mental disorder or mental retardation 9-2. severe drug or alcohol dependence that required inpatient treatment and/or detoxification 9-3. other conditions, such as a serious medical condition, a history of bipolar or schizoaffective disorder, suicidality, possibility of pregnancy, lactation, or inability/unwillingness to use contraception 9-4. contraindicated with Solian® by the product label
10. Study Design: Prospective/ Open label/ Interventional/ Controlled
11. Treatments:
11-1. Study medication - Solian® and there is no comparator medication. 11-2. Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
11-3. For efficacy assessment, psychotic symptoms will be assessed on baseline and 8th week by psychiatrists with positive and negative syndrome scale (PANSS), scale for the assessment of negative symptoms (SANS), scale for the assessment of positive symptoms (SAPS) and clinical global impression scale (CGI).
11-4. For safety assessment, Barnes Akathisia Scale, Simpson-Angus scale and vital signs will be assessed on 8th week of treatment.
11-5. Treatment responders will be defined as patients whose PANSS score reduction by 30% or more and patients whose PANSS score decrease by less than 30% will be assigned to non-responder group.
11-6. The investigators will evaluate the differences of gray matter volume and white matter connectivity between responders and non-responders to amisulpride with images from brain 3T magnetic resonance imaging (MRI) using voxel-based morphometry (VBM) and tract-based spatial statistics (TBSS) at baseline. To examine a possible association between a specific brain region and response to amisulpride, the investigators will use methods based on the definition of regions of interest (ROIs).
11-7. The investigators will evaluate the polymorphisms of COMT and BDNF with molecular genetic analysis using patients' peripheral blood, especially leukocytes at baseline. One-way analysis of variance (ANOVA) will be used to assess variations in clinical symptoms and cognitive function according to COMT and BDNF polymorphisms.
12. Evaluation Criteria:
12-1 Primary endpoints
* Brain structures on the structural MRI will be observed before the treatment starts. Based on the clinical response after treatment, patients will be divided in the two different groups as follow and their baseline brain structure of will be compared:
* Treatment responders and non-responders; Treatment response will be defined as patients whose PANSS score reduce by 30% or more and non-responder as patients whose PANSS score decrease by less than 30% at 8 weeks from baseline.
12-2 Secondary endpoints
* The relationship of baseline brain structures with symptom severity of schizophrenia; Severity will be determined by CGI-S and PANSS at baseline.
* The differences of the polymorphisms of COMT and BDNF with molecular genetic analysis using patients' peripheral blood, especially leukocytes, between the treatment responders and the non-responders
* Efficacy : PANSS, SANS, SAPS, CGI on baseline and 8th week
* Safety : Barnes akathisia scale, Simpson-Angus scale, Vital signs at 8th week
13. Study Budget 13-1. Total Study Cost (euro): 13,848 euro (1 EUR = 1445 KRW) 13-2. Y (year of Study Outline approval): 5,539 EUR 13-3. Y+1: 5,539 EUR 13-4. Beyond Y+1: 2,770 EUR
* Predicting the treatment response of antipsychotic drug in schizophrenia patients has been an issue in psychiatry. However, it is not clear if the findings of structural magnetic resonance imaging (MRI) such as brain gray matter volumes and white matter connectivities, are related to the treatment response of antipsychotic drugs.
* The cognitive and behavioural symptoms of patients with schizophrenia are hypothesized to involve a disruption of neuronal interactions resulting in dysfunctional cognitive integration (Friston et al., 1995, 1996). This hypothesis is supported by reports about a decrease in white matter anatomic connections (Mitelman et al. 2006; Skudlarski et al. 2010; Zalesky et al. 2011) and brain structure alterations, especially decrease in volumes of specific brain regions for patients with schizophrenia. Several studies of brain connectivity have shown that functional connectivity depends strongly on the underlying anatomic structure (Sporns O et al. 2004). At the anatomic level, the pathology of schizophrenia has been related to a wide range of anatomic abnormalities, including ventricular enlargement, associated with anomalous neurodevelopment or neurodegenerative alterations (Shenton ME et al 2001). And schizophrenia is likely to be the result of both general and specific localized changes in both grey and white matter (Knochel C et al. 2012; Konrad A et al. 2008). Savas HA et al. found that responders to risperidone had greater hippocampal volumes than patients who failed to respond to risperidone (Savas HA et al., 2002). Vicente M et al. found an inverse association between striatal size and the degree of clinical improvement, and a direct association between the degree of insular volume deficit and its improvement. The non-responders to risperidone or olanzapine showed a significant decrease in their left rectal gyrus as compared with the responder group. (Vicente M et al., 2010).
* Nielsen et al reported that after 6 weeks of amisulpride treatment, patients with schizophrenia showed an increase in the anticipation-related functional MRI signal (Nielsen et al., 2012). This suggested that amisulpride could affect the brain structures and that responses to amisulpride could be associated by the brain structures as seen previous studies about treatment response to antipsychotics and brain structures. But to date, no study has examined the impact of brain structure alterations on amisulpride treatment for schizophrenia and its potential clinical significance..
2. Study type: Clinical Study Phase IV
3. Number of centers: a single center in Korea
4. Number of subjects: N= 20 patients
5. Study duration and dates (format date : dd/mmm/yyyy) 5-1. Protocol planned date: 01/Apr/2013 5-2. First patient In: 01/Nov/2013 5-3. Last patient In: 01/Oct/2015 5-4. Last patient Out: 01/Dec/2015 5-5. Estimated enrollment duration: 2 years 5-6. Estimated average treatment duration: 8 weeks 5-7. Database lock planned date: 15/Dec/2015 5-8. Estimated Report/Publication date: 31/Dec/2015
6. Indication: Schizophrenia
7. Study Objectives (Primary / Most Important Secondary):
7-1. Primary: To show the differences of the baseline brain structures on the structural MRI between the Solian® treatment responders and the non-responders 7-2. Secondary:
* To show the differences of the baseline polymorphisms of COMT and BDNF with molecular genetic analysis between the Solian® treatment responders and the non-responders; responder defined by PANSS
* To find out the correlates of baseline brain structures with symptom severity of schizophrenia at baseline; symptom severity defined by CGI-S and PANSS
* To assess psychotic symptom improvement after 8th week of Solian® treatment using positive and negative syndrome scale (PANSS), scale for the assessment of negative symptoms (SANS), scale for the assessment of positive symptoms (SAPS) and clinical global impression scale (CGI)
* To assess safety after 8th week of Solian® treatment with Barnes Akathisia Scale, Simpson-Angus scale and vital signs
* To report all serious adverse event (SAE) within 24hrs regardless of relationship to investigational product. SAE or expedited reports are completed including: death, Requiring/prolonging hospitalization, Congenital anomaly/Birth defect, Life-threatening, Persistent/significant disability/incapacity, A procedure result only if symptomatic, considered by the investigator as clinically significant or meaningful or leading to permanent investigational product discontinuation or requiring corrective treatment, A symptomatic overdose, A pregnancy, AESI (adverse event special interest with immediate notification) in AEs( serious or non-serious) that need to be monitored, documented, and managed in a pre-specified manner described in the protocol.
8. Inclusion Criteria:
8-1. between 21 and 60 years of age 8-2. diagnosed with schizophrenia, based on the Structured Clinical Interview for DSM-IV(SCID) 8-3. first or second episode of schizophrenia patient 8-4. the presence of positive or negative symptoms or both, resulting in illness of at least mild severity (≥3 on the Clinical Global Impression (CGI) severity scale
9. Exclusion Criteria:
9-1. evidence of organic mental disorder or mental retardation 9-2. severe drug or alcohol dependence that required inpatient treatment and/or detoxification 9-3. other conditions, such as a serious medical condition, a history of bipolar or schizoaffective disorder, suicidality, possibility of pregnancy, lactation, or inability/unwillingness to use contraception 9-4. contraindicated with Solian® by the product label
10. Study Design: Prospective/ Open label/ Interventional/ Controlled
11. Treatments:
11-1. Study medication - Solian® and there is no comparator medication. 11-2. Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
11-3. For efficacy assessment, psychotic symptoms will be assessed on baseline and 8th week by psychiatrists with positive and negative syndrome scale (PANSS), scale for the assessment of negative symptoms (SANS), scale for the assessment of positive symptoms (SAPS) and clinical global impression scale (CGI).
11-4. For safety assessment, Barnes Akathisia Scale, Simpson-Angus scale and vital signs will be assessed on 8th week of treatment.
11-5. Treatment responders will be defined as patients whose PANSS score reduction by 30% or more and patients whose PANSS score decrease by less than 30% will be assigned to non-responder group.
11-6. The investigators will evaluate the differences of gray matter volume and white matter connectivity between responders and non-responders to amisulpride with images from brain 3T magnetic resonance imaging (MRI) using voxel-based morphometry (VBM) and tract-based spatial statistics (TBSS) at baseline. To examine a possible association between a specific brain region and response to amisulpride, the investigators will use methods based on the definition of regions of interest (ROIs).
11-7. The investigators will evaluate the polymorphisms of COMT and BDNF with molecular genetic analysis using patients' peripheral blood, especially leukocytes at baseline. One-way analysis of variance (ANOVA) will be used to assess variations in clinical symptoms and cognitive function according to COMT and BDNF polymorphisms.
12. Evaluation Criteria:
12-1 Primary endpoints
* Brain structures on the structural MRI will be observed before the treatment starts. Based on the clinical response after treatment, patients will be divided in the two different groups as follow and their baseline brain structure of will be compared:
* Treatment responders and non-responders; Treatment response will be defined as patients whose PANSS score reduce by 30% or more and non-responder as patients whose PANSS score decrease by less than 30% at 8 weeks from baseline.
12-2 Secondary endpoints
* The relationship of baseline brain structures with symptom severity of schizophrenia; Severity will be determined by CGI-S and PANSS at baseline.
* The differences of the polymorphisms of COMT and BDNF with molecular genetic analysis using patients' peripheral blood, especially leukocytes, between the treatment responders and the non-responders
* Efficacy : PANSS, SANS, SAPS, CGI on baseline and 8th week
* Safety : Barnes akathisia scale, Simpson-Angus scale, Vital signs at 8th week
13. Study Budget 13-1. Total Study Cost (euro): 13,848 euro (1 EUR = 1445 KRW) 13-2. Y (year of Study Outline approval): 5,539 EUR 13-3. Y+1: 5,539 EUR 13-4. Beyond Y+1: 2,770 EUR
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Schizophrenia
Schizophreniform Disorder
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
BASIC_SCIENCE
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Solian
Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician
Group Type
EXPERIMENTAL
amisulpride
Intervention Type
DRUG
Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
amisulpride
Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Solian
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* between 21 and 60 years of age
* diagnosed with schizophrenia, based on the Structured Clinical Interview for DSM-IV(SCID)
* first or second episode of schizophrenia patient
* the presence of positive or negative symptoms or both, resulting in illness of at least mild severity (≥3 on the Clinical Global Impression (CGI) severity scale
* diagnosed with schizophrenia, based on the Structured Clinical Interview for DSM-IV(SCID)
* first or second episode of schizophrenia patient
* the presence of positive or negative symptoms or both, resulting in illness of at least mild severity (≥3 on the Clinical Global Impression (CGI) severity scale
Exclusion Criteria
* evidence of organic mental disorder or mental retardation
* severe drug or alcohol dependence that required inpatient treatment and/or detoxification
* other conditions, such as a serious medical condition, a history of bipolar or schizoaffective disorder, suicidality, possibility of pregnancy, lactation, or inability/unwillingness to use contraception
* contraindicated with Solian® by the product label
* severe drug or alcohol dependence that required inpatient treatment and/or detoxification
* other conditions, such as a serious medical condition, a history of bipolar or schizoaffective disorder, suicidality, possibility of pregnancy, lactation, or inability/unwillingness to use contraception
* contraindicated with Solian® by the product label
Minimum Eligible Age
21 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Handok Inc.
INDUSTRY
Sponsor Role
collaborator
CHA University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sang-Hyuk Lee
Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sang-Hyuk Lee, MD., PhD.
Role: PRINCIPAL_INVESTIGATOR
Associate Professor at Bundang CHA hospital
References
Explore related publications, articles, or registry entries linked to this study.
Friston KJ. Theoretical neurobiology and schizophrenia. Br Med Bull. 1996 Jul;52(3):644-55. doi: 10.1093/oxfordjournals.bmb.a011573.
Reference Type
BACKGROUND
Friston KJ, Frith CD. Schizophrenia: a disconnection syndrome? Clin Neurosci. 1995;3(2):89-97.
Reference Type
BACKGROUND
Knochel C, O'Dwyer L, Alves G, Reinke B, Magerkurth J, Rotarska-Jagiela A, Prvulovic D, Hampel H, Linden DE, Oertel-Knochel V. Association between white matter fiber integrity and subclinical psychotic symptoms in schizophrenia patients and unaffected relatives. Schizophr Res. 2012 Sep;140(1-3):129-35. doi: 10.1016/j.schres.2012.06.001. Epub 2012 Jul 19.
Reference Type
BACKGROUND
Konrad A, Winterer G. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon? Schizophr Bull. 2008 Jan;34(1):72-92. doi: 10.1093/schbul/sbm034. Epub 2007 May 7.
Reference Type
BACKGROUND
Mitelman SA, Newmark RE, Torosjan Y, Chu KW, Brickman AM, Haznedar MM, Hazlett EA, Tang CY, Shihabuddin L, Buchsbaum MS. White matter fractional anisotropy and outcome in schizophrenia. Schizophr Res. 2006 Oct;87(1-3):138-59. doi: 10.1016/j.schres.2006.06.016. Epub 2006 Jul 18.
Reference Type
BACKGROUND
Savas HA, Unal B, Erbagci H, Inaloz S, Herken H, Canan S, Gumusburun E, Zoroglu SS. Hippocampal volume in schizophrenia and its relationship with risperidone treatment: a stereological study. Neuropsychobiology. 2002;46(2):61-6. doi: 10.1159/000065413.
Reference Type
BACKGROUND
Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res. 2001 Apr 15;49(1-2):1-52. doi: 10.1016/s0920-9964(01)00163-3.
Reference Type
BACKGROUND
Skudlarski P, Jagannathan K, Anderson K, Stevens MC, Calhoun VD, Skudlarska BA, Pearlson G. Brain connectivity is not only lower but different in schizophrenia: a combined anatomical and functional approach. Biol Psychiatry. 2010 Jul 1;68(1):61-9. doi: 10.1016/j.biopsych.2010.03.035. Epub 2010 May 23.
Reference Type
BACKGROUND
Sporns O, Chialvo DR, Kaiser M, Hilgetag CC. Organization, development and function of complex brain networks. Trends Cogn Sci. 2004 Sep;8(9):418-25. doi: 10.1016/j.tics.2004.07.008.
Reference Type
BACKGROUND
Molina V, Martin C, Ballesteros A, de Herrera AG, Hernandez-Tamames JA. Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci. 2011 Sep;261(6):407-16. doi: 10.1007/s00406-010-0182-2. Epub 2010 Dec 30.
Reference Type
BACKGROUND
Zalesky A, Fornito A, Seal ML, Cocchi L, Westin CF, Bullmore ET, Egan GF, Pantelis C. Disrupted axonal fiber connectivity in schizophrenia. Biol Psychiatry. 2011 Jan 1;69(1):80-9. doi: 10.1016/j.biopsych.2010.08.022. Epub 2010 Oct 29.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMISUL06995
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
Sang-Hyuk Lee
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
NCT00097942
COMPLETED
PHASE2
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
NCT00086593
COMPLETED
PHASE3
Neuroimaging Studies of Neurophysiological Phenotypes in Schizophrenia
NCT01036568
COMPLETED
Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia
NCT00206960
COMPLETED
NA
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
NCT02237235
COMPLETED
PHASE2
Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia
NCT02001103
UNKNOWN
PHASE3
Study on the Gut Microbial Mechanism of Negative Symptoms of Schizophrenia
NCT04533724
UNKNOWN
EARLY_PHASE1
Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study
NCT02714894
UNKNOWN
Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia
NCT00061789
COMPLETED
PHASE2
fMRI Cholinergic Mechanisms in Schizophrenia
NCT01191827
COMPLETED
A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics
NCT02824055
COMPLETED
PHASE1
Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects
NCT02233556
UNKNOWN
NA
Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia
NCT01399437
COMPLETED
Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy
NCT00419653
TERMINATED
PHASE4
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
NCT07145918
RECRUITING
PHASE2
Galantamine for Cognition in People With Schizophrenia
NCT00320736
COMPLETED
PHASE4
Aging and Disease Course: Contributions to Lifespan Neurobiology of Schizophrenia
NCT04951700
ACTIVE_NOT_RECRUITING
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
NCT01448499
WITHDRAWN
NA
Brain Imaging, Attention, and Auditory Processing in Schizophrenia
NCT03068806
COMPLETED
Functional Magnetic Resonance Imaging Study in Schizophrenia Patients and Correlation With Cognitive Impairments
NCT06471179
NOT_YET_RECRUITING
Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia
NCT00001323
COMPLETED
Biomarker Study of Acamprosate in Schizophrenia
NCT00688324
COMPLETED
PHASE4
The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia
NCT00209027
TERMINATED
NA
Cognitive Effects of Nimodipine in Patients With Schizophrenia
NCT03671525
COMPLETED
EARLY_PHASE1